April 12, 2018 04:02 AM EDTUpdated 10:36 AM
Financing
Startups

VC be­liev­ers back a $41M game plan for En­ter­prise Ther­a­peu­tic­s' new group of res­pi­ra­to­ry drugs

John Carroll

Editor & Founder

Alex May­weg wasn’t at­tract­ed to the team at En­ter­prise Ther­a­peu­tics be­cause they had some new, cut­ting-edge tech­nol­o­gy that would set the biotech world on fire …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times